The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Sodium-glucose cotransporter 2 (SGLT2) inhibitors have recently been shown to improve cardiovascular outcomes in patients with type 2 diabetes.”
From Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction: Results of DAPA-HF (2021) · cites this paper as [4]
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
Pitt, B., Zannad, F., Remme, W. J., Cody, R., Castaigne, A., Perez, A., Palensky, J., & Wittes, J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909023411001 · Cited by 9,214
Effects of intensive blood-pressure control in type 2 diabetes mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001286 · Cited by 3,598
Effect of a multifactorial intervention on mortality in type 2 diabetes
Gæde, P., Lund-Andersen, H., Parving, H.-H., & Pedersen, O. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706245 · Cited by 3,465
Statistics in Medicine — Reporting of Subgroup Analyses in Clinical Trials
Wang, R., Lagakos, S. W., Ware, J. H., Hunter, D. J., & Drazen, J. M. (2007) · New England Journal of Medicine · doi:10.1056/nejmsr077003 · Cited by 1,445
Ellison, D. H., Velázquez, H., & Wright, F. S. (1989) · Journal of Clinical Investigation · doi:10.1172/jci113847 · Cited by 294
Bapoje, S. R., Bahia, A., Hokanson, J. E., Peterson, P. N., Heidenreich, P. A., Lindenfeld, J. M., Allen, L. A., & Masoudi, F. A. (2013) · Circulation Heart Failure · doi:10.1161/circheartfailure.112.000003 · Cited by 45
Flagged first, then by citations
Research works printed but not linked: 2
- Toto RD, 2013, J Am Soc Nephrol, 24
- 10.1056/NEJMsr077003 · DOI · Paper page
Cited by
Sorted by citations
Items 401–500 of 698
Altaf, M., Altaf, L. Z., Farahat, F. M., & Althaqafi, A. (2021) · World Family Medicine Journal/Middle East Journal of Family Medicine · doi:10.5742/mewfm.2021.94170 · Cited by 3
THE INTERIM EXPERTS’ COUNCIL RESOLUTION ON THE EMPA-REG OUTCOME TRIAL ISSUES
Shestakova, M. V., Boytsov, S. A., Drapkina, O. M., Demidova, T. Y., Drexel, H., Antsiferov, M. B., Petunina, N. A., Chernikova, N. A., Kalashnikov, V. Y., Bardymova, T. P., et al. (2016) · Rational Pharmacotherapy in Cardiology · doi:10.20996/1819-6446-2016-12-2-186-190 · Cited by 3
Inhibiteur de la DPP-4 ou des SGLT2 après échec de la metformine seule dans le diabète de type 2
Paquot, N., & Scheen, A. J. (2017) · JMIG · doi:10.53738/revmed.2017.13.571.1410 · Cited by 5
İleri evre kalp yetersizliği rehberi
Nalbantgil, S. (2018) · Updates in Cardiology · doi:10.5543/ucard.2018.43153 · Cited by 3
Litke (2020) · Journal of clinical outcomes management · doi:10.12788/jcom.0030 · Cited by 3
Weir (2020) · The Journal of Family Practice · doi:10.12788/jfp.0068 · Cited by 3
Recognition and Management of Hypoglycemia
Shubrook (2020) · The Journal of Family Practice · doi:10.12788/jfp.0069 · Cited by 3
Dissanayake, H. A., Dilrukshi, S., Ratnasamy, V., Soysa, P., Samarathunga, T., Bandara, P., Silva, L. D., & Katulanda, P. (2022) · Primary care diabetes · doi:10.1016/j.pcd.2022.11.005 · Cited by 3
SHOUKRY, M. D. M. M. T. H. S., AMIN, M. S. A. A. A., & Samy, M. (2019) · The Medical Journal of Cairo University/The Medical Journal of Cairo University · doi:10.21608/mjcu.2019.52382 · Cited by 3
Diabetes Mellitus in Patients With Heart Failure
Dianati‐Maleki, N., & Butler, J. (2016) · JACC Heart Failure · doi:10.1016/j.jchf.2016.11.002 · Cited by 3
Plehn, J. F. (2017) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2017.05.013 · Cited by 3
Translating patient related outcome measures into practice—lessons to be learnt
Majeed, W., & Thabit, H. (2018) · Annals of Translational Medicine · doi:10.21037/atm.2018.03.11 · Cited by 3
Weisnagel, S. J. (2018) · Annals of Translational Medicine · doi:10.21037/atm.2018.03.29 · Cited by 3
Game changer: Navigating between challenges and hopes in geropharmacology
Chen, Q., Hartman, R., Dankiv, L., Yan, E., Young, L. H., & Barsotti, R. (2025) · Advances in pharmacology · doi:10.1016/bs.apha.2025.02.007 · Cited by 2
Mehr, K. N., Shokry, J., Ahangar, H. G., Pirshahid, M. E., Seyedalipour, S. F., Emami, A., & Meftah, N. (2025) · Hepatitis Monthly · doi:10.5812/hepatmon-150453 · Cited by 3
Liu, H., Li, Y., Zhou, X., Chen, T., Liu, Y., Hu, S., Wang, C., Wang, Q., Xu, J., Zhou, X., et al. (2025) · Cardiovascular Toxicology · doi:10.1007/s12012-025-10035-1 · Cited by 2
Yao, Q., Liu, H., Wang, X., Zhang, Z., Xie, H., Xie, C., & Gao, H. (2026) · Biological Research · doi:10.1186/s40659-025-00665-8 · Cited by 5
Liu, H.-Y., Lv, Y., Chen, Y., Dai, C., Zeng, H.-Y., Deng, C.-Y., Yang, H., Zhang, M.-Z., Wu, S., Rao, F., et al. (2026) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2026.178520 · Cited by 2
Zhou, X., Pan, Y., Hua, K., & Yang, X. (2026) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm39400 · Cited by 2
Abdi, H., Locke, E., Fitzpatrick, R., & Oake, J. S. (2018) · Canadian Urological Association Journal · doi:10.5489/cuaj.5635 · Cited by 2
Nurse Practitioner–Directed Cardio-Diabetes Pilot Program
Bryant, E., Janaszek, K. B., Nejedly, M., Li, E., Bouvier, M. J., Schroeder, K., Khandelwal, A., Lough, M. E., Lamendola, C. A., Reisenberg, A., et al. (2020) · The Journal for Nurse Practitioners · doi:10.1016/j.nurpra.2020.05.009 · Cited by 2
Infectious complications of newer agents in the fight against diabetes
Stover, K. R., Hugh, E., Sherman, J. J., Malinowski, S. S., Berdahl, G. J., & Riche, D. M. (2020) · The Nurse Practitioner · doi:10.1097/01.npr.0000718508.65708.a1 · Cited by 2
Metformin kullanımının akut iskemik inmede şiddet ve prognoz üzerine etkisi
Allahverdiyev, T., Sorgun, M. H., Işıkay, C. T., & Yücesan, C. (2020) · Turkish Journal of Cerebrovascular Diseases · doi:10.5505/tbdhd.2020.75768 · Cited by 2
Mitochondrial Diabetes Treated With a Sodium-Glucose Co-Transporter 2 Inhibitor
Hamasaki, H. (2019) · Journal of Endocrinology and Metabolism · doi:10.14740/jem627 · Cited by 2
School Teachers’ Knowledge and Attitude toward School Students with Epilepsy
Alsugair, R. S., Alyabis, M. A., Algadi, M. A., Attieh, A. I., Juha, L. A., Alawa, R. G., Alghannam, S. G., Alsaadoon, N. Z., El-Sayed, N., & Alfadeel, M. A. (2021) · World Family Medicine Journal/Middle East Journal of Family Medicine · doi:10.5742/mewfm.2021.94183 · Cited by 2
El-Gamal, F., Alsubhi, N., Badr, S., Althaqafi, N., Al-Qadasi, F., & Hammed, M. (2021) · World Family Medicine Journal/Middle East Journal of Family Medicine · doi:10.5742/mewfm.2021.94179 · Cited by 2
SGLT2 Inhibitor: A Cardio-Renal Metabolic Pill
Krishnan, R., Subramanian, R., & Selvarajan, R. (2023) · International Journal of Health Sciences and Research · doi:10.52403/ijhsr.20230119 · Cited by 2
Expert viewpoint on the position of Vildagliptin in a cardiology clinic in Indian clinical settings
Das, D. R., Shah, C. P., & Warrier, S. B. (2023) · World Journal of Advanced Research and Reviews · doi:10.30574/wjarr.2023.17.2.1252 · Cited by 2
Diabetic cardiomyopathy—an under-recognized cause of heart failure in diabetic patients
Šarun, D., Kanič, V., & Sinkovič, A. (2021) · Acta Medico-Biotechnica · doi:10.18690/actabiomed.200 · Cited by 2
Faruqui, A. A. (2023) · Journal of Medicine · doi:10.3329/jom.v24i1.64903 · Cited by 2
Update on Sodium Glucose Cotransporter Type 2 Inhibitors Use in Kidney Transplant Patients
Salvadori, M., Rosati, A., & Rosso, G. (2024) · Transplantology · doi:10.3390/transplantology5030022 · Cited by 2
Kim, H. (2025) · CardioMetabolic Syndrome Journal · doi:10.51789/cmsj.2025.5.e4 · Cited by 2
Hiran, S., Singh, A., & Sial, P. (2018) · Journal of Diabetology · doi:10.4103/jod.jod_28_17 · Cited by 2
Yanagawa, T. (2018) · Journal of Clinical Medicine Research · doi:10.14740/jocmr3587w · Cited by 2
Admission blood glucose as a prognostic indicator in patients with acute myocardial infarction
Russel, R., Ranjith, R., & Sartorius, B. K. D. (2019) · SA Heart · doi:10.24170/16-2-3641 · Cited by 2
Jahangiri, D., Padhi, U. N., Verma, H. K., Bhaskar, L. V., Valizadeh, R., & Nasri, H. (2021) · Journal of Renal Injury Prevention · doi:10.34172/jrip.2021.35 · Cited by 2
NEW GDMT OF HEART FAILURE WITH REDUCED EJECTION FRACTION (HFrEF): THE ROLE OF DAPAGLIFLOZIN
Sukandi, E., Farianty, A., & Maulana, E. Z. (2022) · Conferences of Medical Sciences Dies Natalis Faculty of Medicine Universitas Sriwijaya · doi:10.32539/confmednatalisunsri.v4i1.91 · Cited by 2
Hyperglycemia, hypoglycemia and glycemic variability in the elderly: a fatal triad?
Monami, M., & Aleffi, S. (2016) · Monaldi Archives for Chest Disease · doi:10.4081/monaldi.2015.726 · Cited by 2
Sodium Glucose Cotransporter-2 Inhibitors in Clinical Practice: Impact beyond Glycemic Control
Rao, N. K., & KUMAR, K. M. P. (2016) · Hypertension Journal · doi:10.5005/jp-journals-10043-0035 · Cited by 2
Mapping Progress in Reducing Cardiovascular Risk with Kidney Disease
Bansal, N. (2018) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.01930218 · Cited by 2
Chaves, W. G., Martínez, L., Díaz, D., Hernández, D., & Sanabria, M. C. (2019) · Revista Colombiana de Endocrinología Diabetes & Metabolismo · doi:10.53853/encr.6.4.545 · Cited by 2
Takamiya, Y., Kobayashi, K., Kudo, T., Okuda, T., Okamura, K., Shirai, K., & Urata, H. (2020) · Journal of Clinical Medicine Research · doi:10.14740/jocmr4224 · Cited by 2
Cardiovascular Comorbidity and Diabetes Mellitus (Clinical Case)
Ганцгорн, Е. В., Nasyrova, V. A., Shahbanov, A. S., & Alekseev, A. N. (2020) · Medicina · doi:10.29234/2308-9113-2020-8-1-34-50 · Cited by 2
Strategic Assessment of Rational Drugs use in Tertiary Care Hospital Peshawar, Pakistan
Khan, M. M. H. (2020) · Advances in Clinical Toxicology · doi:10.23880/act-16000179 · Cited by 2
The unexpected benefits of sodium glucose co-transporter 2 (SGLT2) inhibitors
Stewart, R., & Chan, C. (2022) · New Zealand Medical Journal · doi:10.26635/6965.5818 · Cited by 2
Cardiorenal disease management in type 2 diabetes: An expert consensus
Mohan, V., Singh, A. K., Zargar, A. H., Almeida, A. F., Bhalla, A. K., Mohan, J. C., Dalal, J. J., Sahay, M., Mohanan, P. P., Maitra, S., et al. (2022) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2022.102661 · Cited by 2
Bharti, J., Wankhade, A. M., Vyas, J. V., & Paithankar, V. (2023) · International Journal of Pharmaceutical Sciences and Medicine · doi:10.47760/ijpsm.2023.v08i05.017 · Cited by 2
A Succinct Analysis of Hypertension and its Management Strategies
Gupta, P., & Parashar, A. K. (2023) · International Journal of Newgen Research in Pharmacy & Healthcare · doi:10.61554/ijnrph.v1i1.2023.24 · Cited by 3
Shrestha, A. B., Halder, A., Rajak, K., Jha, S. K., Lamichhane, R., Oishee, A. N., Chowdary, N. T., Pokharel, P., Shrestha, S., Adhikari, L., et al. (2024) · SAGE Open Medicine · doi:10.1177/20503121241261204 · Cited by 2
Sodium-glucose cotransporter 2 inhibitor use: A pharmaco-ergonomic qualification tool
Kalra, S., Unnikrishnan, A., Baruah, M. P., Kawatra, P., & Ved, J. (2017) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_184_17 · Cited by 2
Lunder, M., Janić, M., Šabović, M., & Janež, A. (2018) · Slovenian Medical Journal · doi:10.6016/zdravvestn.2705 · Cited by 2
Singh, A. K., & Singh, R. (2019) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_12_19 · Cited by 2
The year in cardiology: heart failure. The year in cardiology 2019.
Cleland, J. G. F., Lyon, A. R., McDonagh, T. A., & McMurray, J. J. V. (2020) · SA Heart · doi:10.24170/17-1-4023 · Cited by 2
Ko, F. (2020) · Journal of clinical outcomes management · doi:10.12788/jcom.0010 · Cited by 2
Empagliflozin-induced euglycemic diabetic ketoacidosis in type 2 diabetes mellitus
Albugami, M. M., Ahmed, M., & Alobaid, D. (2020) · Saudi Journal of Medicine and Medical Sciences · doi:10.4103/sjmms.sjmms_325_20 · Cited by 2
Acute Effects of Preventing Heart Failure by Sodium-Glucose Cotransporter 2 Inhibitors
Yanai, H. (2021) · Cardiology Research · doi:10.14740/cr1315 · Cited by 2
Prescription Patterns for Empagliflozin among Adults with Diabetes Mellitus in Dhaka, Bangladesh
Shill, D. K., Jahan, S., Reza, M. S., Shohan, S. M., & Rajbangshi, J. C. (2021) · Journal of Pharmaceutical Research International · doi:10.9734/jpri/2021/v33i46b32945 · Cited by 1
Chaitoff, A. M., Niforatos, J. D., Gong, J., & Fischer, M. A. (2022) · Journal of General Internal Medicine · doi:10.1007/s11606-021-07284-5 · Cited by 1
An insight to the diabetic ketoacidosis and lactic acidosis among the SARS-COV2 infected individuals
Al-Sa'idy, H. A. H., Al‐Snafi, A. E., & Alyousif, B. (2022) · Magna Scientia Advanced Biology and Pharmacy · doi:10.30574/msabp.2022.6.1.0071 · Cited by 1
Qarni, A. A. A., AlSubaiee, M., Husain, M., Alkhazmari, G., AlQahtani, A., Aldossary, I., Gado, W., Albahrani, Z., AlMukhaylid, S., Alarfaj, A., et al. (2023) · Series of Endocrinology Diabetes and Metabolism · doi:10.54178/jsedmv5i2004 · Cited by 1
Evolution of Management of Diabetes Mellitus
Uddin, K. N. (2024) · Bangladesh Journal of Medicine · doi:10.3329/bjm.v35i1.70738 · Cited by 1
Does Empaglifozin, a Popular SGLT2 Inhibitor, Increase Arrhythmia?
Kaya, O. K. (2024) · Bulletin of Cardiovasculer Academy · doi:10.4274/kvbulten.galenos.2024.57966 · Cited by 1
Li, Y., Zhang, W., & Li, R. (2025) · Medicine · doi:10.1097/md.0000000000044215 · Cited by 3
Yu, C., Zhang, X., Wang, R., Zhang, C., Gao, Y., Yixin, W. A. N. G., Lv, L., Wang, Z., & Zhang, H. (2026) · Phytomedicine · doi:10.1016/j.phymed.2026.157975 · Cited by 1
Ren, X., Gao, D., Yun, R., Liu, X., Di, C., Hu, Z., Zhang, X., Tian, Z., & Yang, Z. (2026) · Nature Communications · doi:10.1038/s41467-026-71424-w · Cited by 1
Nan, X., Tang, L., Fang, X., Yang, X., & Kang, Y. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1758096 · Cited by 1
Wen, S., Wang, C., Xu, Z., Chen, L., He, Y., Ren, Y., Yuan, Y., Li, Y., Dong, M., Gong, M., et al. (2026) · Cardiovascular Diabetology · doi:10.1186/s12933-026-03164-6 · Cited by 1
Empagliflozin and metformin combination therapy in Type 2 diabetes mellitus
Jeyalalitha, R. (2015) · International Journal of Basic & Clinical Pharmacology · doi:10.18203/2319-2003.ijbcp20151382 · Cited by 1
Euglycemic diabetic ketoacidosis with SGLT2 inhibitors in lean type 2 diabetes
Kim, M.-K. (2016) · Integrative Obesity and Diabetes · doi:10.15761/iod.1000157 · Cited by 1
Antidiabetika ved type 2-diabetes – forvalter vi ny kunnskap riktig?
Svingen, G. F. T., & Løland, K. H. (2017) · Tidsskrift for Den norske legeforening · doi:10.4045/tidsskr.17.0002 · Cited by 1
Options thérapeutiques chez un patient diabétique de type 2 mal contrôlé par une insuline basale
Scheen, A. J., & Paquot, N. (2017) · JMIG · doi:10.53738/revmed.2017.13.571.1416 · Cited by 1
Hakoshima, M., Yanai, H., Kakuta, K., & Adachi, H. (2018) · Journal of Clinical Medicine Research · doi:10.14740/jocmr3392w · Cited by 1
Hirai (2020) · Journal of clinical outcomes management · doi:10.12788/jcom.0013 · Cited by 1
Özışık, H., Çetinkalp, Ş., Candemir, A., Süner, A., & Nalbantgil, S. (2020) · Journal of Integrative Cardiology · doi:10.15761/jic.1000296 · Cited by 1
New Perspectives in COPD Management
Yawn (2021) · The Journal of Family Practice · doi:10.12788/jfp.0220 · Cited by 1
Gestion de la médication pour l’insuffisance cardiaque avec fraction d’éjection réduite
Barry, A. R., Kosar, L., Koshman, S. L., & Turgeon, R. D. (2021) · Canadian Family Physician · doi:10.46747/cfp.6712e329 · Cited by 1
Euglycemic Diabetic Ketoacidosis in a Diabetic Patient Treated with SGLT2 Inhibitor
Lavrynenko, O., Hector, S., Amando, G., Qazi, R., & Leopoldo, C. (2021) · Clinical Diabetes and Research · doi:10.36959/647/497 · Cited by 1
Pande, R. L., & Creager, M. A. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-35762-3.00148-7 · Cited by 2
Real World Data Workshop Group CSPS/Health Canada (2020) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.18433/jpps31051 · Cited by 1
Effectiveness of Community Mental Health Service in Oman: A Pilot Study
Al-Jadidi, S., Aboalatta, A. S., Al-Rahbi, I., Al-Harrasi, M., AlRauzaiqi, H., Sabeih, M. A., AlGammari, T., & Al-Shammakhi, A. (2021) · World Family Medicine Journal/Middle East Journal of Family Medicine · doi:10.5742/mewfm.2021.94180 · Cited by 1
HIPERTENSÃO E DIABETES: CONCEITOS ATUAIS NA TERAPÊUTICA
Faculdade de Medicina de São José do Rio Preto (FAMERP), S., Cosenso‐Martin, L. N., Yugar‐Toledo, J. C., Faculdade de Medicina de São José do Rio Preto (FAMERP), S., Vilela-Martin, J. F., & Faculdade de Medicina de São José do Rio Preto (FAMERP), S. (2021) · Revista Brasileira de Hipertensão · doi:10.47870/1519-7522/20212803213-18 · Cited by 3
Nyshchuk-Oliinyk, N. B. (2022) · Психологічне здоров’я · doi:10.32689/2663-0672-2022-1-11 · Cited by 1
Baker, J., Sundborn, G., Lesa, F., King, G., Vennell, K., Kozak, H., & Pickering, K. (2023) · New Zealand Medical Journal · doi:10.26635/6965.5869 · Cited by 1
SGLT2 Inhibitors: Emerging Drugs in Heart Failure
Cho, D. (2023) · Korean Journal of Medicine · doi:10.3904/kjm.2023.98.2.59 · Cited by 1
Gómez-García, D. M., Barragán, L. B., & García‐Perdomo, H. A. (2023) · REC CardioClinics · doi:10.1016/j.rccl.2023.09.008 · Cited by 4
rafla, M., Abdelraheem, M., Hareedy, M. S., & Elsaughier, S. M. (2023) · Aswan University Medical Journal/Aswan University Medical Journal · doi:10.21608/aumj.2023.230195.1063 · Cited by 1
What Do We Know about Flozins: New, Pleiotropic Drugs
Wojciechowska, E., & Okopień, B. (2023) · Journal of Health Study and Medicine · doi:10.2478/jhsm-2023-0013 · Cited by 1
Critical evaluation of cohort study results
Lund, L. C., Pottegård, A., Sørensen, H. T., & Hallas, J. (2024) · Ugeskrift for Læger · doi:10.61409/v06230401 · Cited by 1
New advances in the treatment and diagnosis of hypertension in primary care: a literature review
Chuquitarco, Y. C. Q., Quilligana, S. F. M., Andrade, V. J. G., López, T. E. H., & Sánchez, P. M. C. (2024) · Sapienza International Journal of Interdisciplinary Studies · doi:10.51798/sijis.v5i1.739 · Cited by 1
Bindu, A. H., Reddy, N. A., Vamshikrishna, P., Deshpande, S., & Javid, S. M. A. M. (2024) · International Journal of Innovative Science and Research Technology (IJISRT) · doi:10.38124/ijisrt/ijisrt24apr1750 · Cited by 1
Diabesity and microvascular disease: the impact of weight loss
Farid, S., Bashir, B., Hamad, A., Dhage, S. S., Ho, J. H., Soran, H., & Adam, S. (2024) · British Journal of Diabetes · doi:10.15277/bjd.2024.438 · Cited by 1
Xie, H., & Jiang, M.-J. (2024) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s459368 · Cited by 1
EMPA-REG OUTCOME trial and Canagliflozin Cardiovascular Assessment Study: Looking beyond the obvious
Ahmed, R., & Kawatra, P. (2017) · BLDE University Journal of Health Sciences · doi:10.4103/bjhs.bjhs_19_17 · Cited by 1
Murata, M., Adachi, H., Nakade, T., & Oshima, S. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2018.09.001 · Cited by 1
Sodium-Glucose Cotransporter 2 Inhibitors in the Treatment of Type 2 Diabetes
Παπάνας, Ν. (2018) · Archives of Diabetes & Obesity · doi:10.32474/ado.2018.01.000111 · Cited by 1
Patoulias, D. (2019) · Archives of Medical Science - Atherosclerotic Diseases · doi:10.5114/amsad.2019.83302 · Cited by 1
Oral Hypoglycemics in Patients with Type 2 Diabetes and Peripheral Artery Disease
Rannelli, L., Kaplovitch, E., & Anand, S. S. (2019) · Canadian Journal of General Internal Medicine · doi:10.22374/cjgim.v14i2.282 · Cited by 1
Kusunoki, M., Sato, D., Sakazaki, T., Miyata, T., Tsutsumi, K., & Oshida, Y. (2020) · Drug Research · doi:10.1055/a-1070-8783 · Cited by 1
Prevention of type 2 diabetes in patients with chronic heart failure
Павликова, Е. П., Sorokina, A. G., & Potapenko, A. V. (2020) · Clinical pharmacology and therapy · doi:10.32756/0869-5490-2020-1-67-74 · Cited by 1
Diabetes, pre-diabetes and cardiovascular diseases in light of the 2019 ESC Guidelines
Zandecki, Ł., Janion−Sadowska, A., Kurzawski, J., & Janion, M. (2020) · Medical Studies · doi:10.5114/ms.2020.96796 · Cited by 1
Metadata
- Authors
- Sarafidis, P. A., & Τσάπας, Α.
- Affiliations
- Aristotle University of Thessaloniki (GR)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2016-03-17
- Volume
- 374
- Issue
- 11
- Pages
- 1092-1094
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2297835124
- Cited by
- 700
- References
- 9
- Citations by year
- 2026: 21 · 2025: 26 · 2024: 77 · 2023: 91 · 2022: 71 · 2021: 95 · 2020: 93 · 2019: 61 · 2018: 57 · 2017: 62 · 2016: 34
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Keywords
- empagliflozin, type 2 diabetes, cardiovascular outcomes, mortality, SGLT2 inhibitors, cardiovascular risk reduction
- MeSH terms
- Benzhydryl Compounds, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Female, Glucosides, Humans, Hypoglycemic Agents, Male
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
